source
- Osivax shifts to combination strategy after Phase 2b flu vaccine setbackOsivax, a French biotech, reported that its lead influenza vaccine candidate did not meet primary endpoints in a Phase 2b study. The trial, which evaluated the vaccine as a standalone product, sho…
- Webinar Explores How US Biotechs Can Compete and Collaborate with China’s Growing IndustryBioSpace is hosting a webinar titled "The China question: Can US biotechs lead as investment heads east?" on October 15, 2026. The event will feature a panel of experts who will discuss how China i…